Methods for treatment of diseases
View Patent ↗The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
1. A method of reducing tissue damage or toxicity resulting from radiation therapy, chemotherapy or a combination thereof, the tissue damage or toxicity being modulated by superoxide dismutase activity in a human patient, the method comprising parenterally administering to the patient 25 to 450 mg of a superoxide dismutase mimetic at a rate of at least 100 mg/hr, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
and X and Y are independently halo ligands.
2. The method of claim 1 , wherein 50 mg of the superoxide dismutase mimetic is administered to the patient.
3. The method of claim 1 , wherein 100 mg of the superoxide dismutase mimetic is administered to the patient.
4. The method of claim 1 , wherein the superoxide dismutase mimetic is administered intravenously.
5. The method of claim 1 , wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein the superoxide dismutase mimetic is administered in the form of the unit dose formulation of claim.
7. The method of claim 1 , wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.
8. The method of claim 1 , wherein X and Y are chloro ligands.
9. The method of claim 1 , wherein 25 to 200 mg of the superoxide dismutase mimetic is administered to the patient.
10. The method of claim 1 , wherein 25 mg of the superoxide dismutase mimetic is administered to the patient.
11. The method of claim 1 , wherein 75 mg of the superoxide dismutase mimetic is administered to the patient.
12. The method of claim 1 , wherein the superoxide dismutase mimetic is administered at a rate of 100 mg/hr.
13. The method of claim 1 , wherein the superoxide dismutase mimetic is administered at a rate of 200 mg/hr.
14. The method of claim 12 , wherein the superoxide dismutase mimetic is administered at a rate of 450 mg/hr.
15. The method of claim 1 , wherein 25 mg of the superoxide dismutase mimetic is administered at a rate of 100 mg/hr.
16. The method of claim 1 , wherein 50 mg of the superoxide dismutase mimetic is administered at a rate of 200 mg/hr.
17. The method of claim 1 , wherein the administration provides an exposure as measured by an area under the curve (AUC) of 4,000 to 10,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma.
18. The method of claim 1 , wherein the administration occurs within a 15 minute time period.
19. The method of claim 1 , wherein the administration occurs within a 30 minute time period.
20. The method of claim 1 , wherein the administration occurs within a 60 minute time period.
21. The method of claim 1 , wherein the tissue damage or toxicity results from the administration of radiation therapy to the patient.
22. The method of claim 1 , wherein the tissue damage or toxicity results from the administration of chemotherapy to the patient.